RANI - NASDAQ
Rani Therapeutics Holdings, Inc.
$0.88
+2.9%Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
At a Glance
Live SnapshotRani Therapeutics Holdings, Inc. Management Team
Ms. Kate McKinley M.B.A.
Chief Business Officer
Mr. Talat Imran
Chief Executive Officer & Director
Compensation
$105,818
Mr. Svai S. Sanford
Chief Financial Officer
Compensation
$416,000
Dr. Mir Hashim
Chief Scientific Officer
Compensation
$416,000
Mr. Mir A. Imran
Executive Chairman
Compensation
$40,000
Mr. Eric Groen J.D.
General Counsel
Ms. Arvinder Dhalla
Vice President of Clinical Development
Ms. Bella Vazquez
Vice President of Human Resources
Mr. Alireza Javadi
Vice President of Technical Operations
Rani Therapeutics Holdings, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.27M and sold $15.71M worth of RANI shares, resulting in $14.44M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
2.2M
1.21M
5.9M
15.71M
-14.5M
-$14.50M
9-12 Months
120.0K
63.36K
0
0.00
+63K
+$63K
Top Buyers
Imran Mir A
Director, 10 Percent Owner:
$1.00M
Bailey Vasudev Jaiprakash
Director
$209K
Mckinley Kate
Officer: Chief Business Officer
$63K
Top Sellers
South Cone Investments Limited Partnership
10 Percent Owner
$15.71M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $14.44M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
SEC Filings
RANI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 16, 2026 | May 28, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 16, 2025 | May 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 17, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 11, 2023 | May 25, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 13, 2022 | May 25, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.